Critical Outcome Technologies Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Critical Outcome Technologies Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Critical Outcome Technologies Inc. - Product Pipeline Review - 2014', provides an overview of the Critical Outcome Technologies Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Critical Outcome Technologies Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Critical Outcome Technologies Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Critical Outcome Technologies Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Critical Outcome Technologies Inc.'s pipeline products

Reasons to buy

- Evaluate Critical Outcome Technologies Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Critical Outcome Technologies Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Critical Outcome Technologies Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Critical Outcome Technologies Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Critical Outcome Technologies Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Critical Outcome Technologies Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Critical Outcome Technologies Inc. Snapshot 5
Critical Outcome Technologies Inc. Overview 5
Key Information 5
Key Facts 5
Critical Outcome Technologies Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Critical Outcome Technologies Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Critical Outcome Technologies Inc. - Pipeline Products Glance 11
Critical Outcome Technologies Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Critical Outcome Technologies Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Critical Outcome Technologies Inc. - Drug Profiles 14
Small Molecule to Antagonize CSF1R, FLT3, PDGFR and Tie-2 for Acute Myelocytic Leukemia 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
COTI-2 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
COTI-219 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
COTI-4 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
COTI-58 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule to Antagonize VEGF-R and PDGF-R for Multiple Sclerosis 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Inhibit CDKs for Colorectal Cancer 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Inhibit HIV-1 Integrase for HIV-1 Infection 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule to Inhibit Microtubulin for Colorectal Cancer 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule to Inhibit Thymidylate Synthase for Colorectal Cancer 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules for CNS Scarring 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules for Small Cell Lung Cancer 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit Angiogenesis for Undisclosed Indication 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Critical Outcome Technologies Inc. - Pipeline Analysis 32
Critical Outcome Technologies Inc. - Pipeline Products by Target 32
Critical Outcome Technologies Inc. - Pipeline Products by Route of Administration 34
Critical Outcome Technologies Inc. - Pipeline Products by Molecule Type 35
Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action 36
Critical Outcome Technologies Inc. - Recent Pipeline Updates 37
Critical Outcome Technologies Inc. - Locations And Subsidiaries 42
Head Office 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Critical Outcome Technologies Inc., Key Information 5
Critical Outcome Technologies Inc., Key Facts 5
Critical Outcome Technologies Inc. - Pipeline by Indication, 2014 8
Critical Outcome Technologies Inc. - Pipeline by Stage of Development, 2014 9
Critical Outcome Technologies Inc. - Monotherapy Products in Pipeline, 2014 10
Critical Outcome Technologies Inc. - Phase I, 2014 11
Critical Outcome Technologies Inc. - Preclinical, 2014 12
Critical Outcome Technologies Inc. - Discovery, 2014 13
Critical Outcome Technologies Inc. - Pipeline by Target, 2014 33
Critical Outcome Technologies Inc. - Pipeline by Route of Administration, 2014 34
Critical Outcome Technologies Inc. - Pipeline by Molecule Type, 2014 35
Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action, 2014 36
Critical Outcome Technologies Inc. - Recent Pipeline Updates, 2014 37